首页> 美国卫生研究院文献>other >Human adrenomedullin combined with human adrenomedullin binding protein-1 is protective in gut ischemia and reperfusion injury in the rat
【2h】

Human adrenomedullin combined with human adrenomedullin binding protein-1 is protective in gut ischemia and reperfusion injury in the rat

机译:人肾上腺髓质素结合人肾上腺髓质素结合蛋白-1对大鼠肠缺血和再灌注损伤具有保护作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Previous studies have demonstrated that co-administration of rat adrenomedullin (AM) and human AM binding protein-1 (AMBP-1) has various beneficial effects following adverse circulatory conditions. In order to reduce rat proteins to elicit possible immune responses in humans, we determined the effect of human AM combined with human AMBP-1 after intestinal ischemia and reperfusion (I/R). Intestinal ischemia was induced in the rat by occluding the superior mesenteric artery for 90 min. At 60 min after the beginning of reperfusion, human AM/AMBP-1 at 3 different dosages was administered intravenously over 30 min. At 240 min after the treatment, blood and tissue samples were harvested and measured for pro-inflammatory cytokines (i.e., TNF-α and IL-6), myeloperoxidase activities in the gut and lungs, and cleaved caspase-3 expression in the lungs, as well as serum levels of hepatic enzymes and lactate. In additional groups of animals, a 10-day survival study was conducted. Results showed that administration of human AM/AMBP-1 reduced pro-inflammatory cytokines, attenuated organ injury, and improved the survival rate in a seemingly dose-response fashion. Co-administration of the highest dose of human AM/AMBP-1 in this study had the optimal therapeutic effect in the rat model of intestinal I/R.
机译:先前的研究表明,大鼠肾上腺髓质素(AM)和人AM结合蛋白1(AMBP-1)的共同给药在不利的循环条件下具有多种有益作用。为了减少大鼠蛋白质以引起人类可能的免疫反应,我们确定了人类AM与人类AMBP-1在肠缺血和再灌注(I / R)后的作用。通过阻塞肠系膜上动脉90分钟来诱导大鼠肠缺血。再灌注开始后60分钟,在30分钟内静脉内施用3种不同剂量的人AM / AMBP-1。治疗后240分钟,收集血液和组织样本,并测量促炎性细胞因子(即TNF-α和IL-6),肠和肺中的髓过氧化物酶活性以及肺中caspase-3的表达,以及血清肝酶和乳酸水平。在另外一组动物中,进行了10天生存研究。结果表明,人AM / AMBP-1的给药以看似剂量反应的方式减少了促炎性细胞因子,减轻了器官损伤,并提高了存活率。在这项研究中,最高剂量的人AM / AMBP-1的共同给药在肠道I / R大鼠模型中具有最佳治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号